Clopidogrel BisulfateThird Party Manufacturing in India

Clopidogrel Bisulfate works by inhibiting platelet aggregation through selective and irreversible binding to the P2Y12 adenosine diphosphate (ADP) receptor on platelets. This prevents ADP from activating the glycoprotein GPIIb/IIIa complex, which is the final common pathway for platelet aggregation. As a prodrug, clopidogrel requires hepatic activation via CYP450 enzymes to form its active metabolite. The active metabolite then targets the P2Y12 receptor on the platelet surface, blocking ADP-mediated platelet activation and cross-linking by fibrinogen. This antiplatelet effect persists for the lifetime of the platelet because the binding is irreversible. Unlike aspirin, which inhibits cyclooxygenase and thromboxane A2 production, clopidogrel directly targets the ADP receptor pathway, providing complementary antiplatelet activity. The combination of aspirin and clopidogrel is therefore commonly used in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention with stent placement. Clopidogrel is also preferred in patients who cannot tolerate aspirin or who have established peripheral arterial disease, where it has been shown to reduce cardiovascular events. Its role in secondary prevention of atherothrombotic events makes it one of the most widely prescribed antiplatelet agents globally.

Therapeutic Uses

Clopidogrel Bisulfate is prescribed for the reduction of atherothrombotic events in patients with cardiovascular disease:

• Acute Coronary Syndrome: Used in combination with aspirin for patients with non-ST-segment elevation ACS or ST-elevation myocardial infarction, reducing the risk of recurrent ischemic events.
• Recent Myocardial Infarction or Stroke: Reduces the risk of subsequent cardiovascular events in patients who have already experienced an MI or ischemic stroke.
• Peripheral Arterial Disease: Effective in reducing cardiovascular morbidity and mortality in patients with established peripheral artery disease.
• Post-Percutaneous Coronary Intervention: Essential for preventing in-stent thrombosis in patients receiving bare-metal or drug-eluting stents.

Why Manufacturers Choose Clopidogrel Bisulfate

Clopidogrel Bisulfate is one of the highest-volume cardiovascular APIs manufactured in India, with consistent demand from both the domestic market and export destinations including the US, Europe, and emerging markets. The molecule has a well-established safety profile, multiple pharmacopoeial grade options, and is straightforward to formulate into tablet dosage forms. Its inclusion in the WHO Model List of Essential Medicines further reinforces its commercial viability for third-party manufacturers and PCD franchise operators. Indian manufacturers benefit from established supply chains for the API and advanced formulation capabilities for 75mg tablets, making Clopidogrel Bisulfate a staple offering for any Cardiac category portfolio.